Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

Autor:	Nooka AK; Winship Cancer Institute, Division of Hematology and Oncology, Emory University-School of Medicine, Atlanta. Electronic address: anooka@emory.edu., Nabhan C; Division of Hematology/Oncology, Advocate Lutheran General Hospital and Oncology Specialists, Park Ridge., Zhou X; RTI Health Solutions, Research Triangle Park., Taylor MD; Genentech, South San Francisco., Byrtek M; Genentech, South San Francisco., Miller TP; Section of Hematology/Oncology, University of Arizona, Tucson., Friedberg JW; Department of Medicine, James P. Wilmont Cancer Center, Rochester., Zelenetz AD; Department of Medicine, Lymphoma Program, Memorial Sloan-Kettering Cancer Center, New York., Link BK; Oncology and Bone & Marrow Transplantation, Division of Hematology, University of Iowa, Iowa City., Cerhan JR; Department of Health Sciences Research, Mayo Clinic-College of Medicine, Rochester., Dillon H; The Leukemia & Lymphoma Society, White Plains, USA., Sinha R; Winship Cancer Institute, Division of Hematology and Oncology, Emory University-School of Medicine, Atlanta., Shenoy PJ; Winship Cancer Institute, Division of Hematology and Oncology, Emory University-School of Medicine, Atlanta., Levy D; Genentech, South San Francisco., Dawson K; Genentech, South San Francisco., Hirata JH; Genentech, South San Francisco., Flowers CR; Winship Cancer Institute, Division of Hematology and Oncology, Emory University-School of Medicine, Atlanta.
Jazyk:	angličtina
Zdroj:	Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2013 Feb; Vol. 24 (2), pp. 441-448. Date of Electronic Publication: 2012 Oct 05.
DOI:	10.1093/annonc/mds429
Abstrakt:	Background: Because follicular lymphoma (FL) patients have heterogeneous outcomes, the FL international prognostic index (FLIPI) was developed to risk-stratify patients and to predict survival. However, limited data exist regarding the role of FLIPI in the era of routine first-line rituximab (R) and R-chemotherapy regimens and in the setting of community oncology practices. Patients and Methods: We evaluated the outcome data from the National LymphoCare Study (NLCS), a prospective, observational cohort study, which collects data on patients with FL in the United States (US) community practices. Results: Among 1068 male and 1124 female patients with FLIPI data, most were treated in US community practices (79%); 35% were FLIPI good risk, 30% intermediate risk, and 35% poor risk. FLIPI risk groups were significant predictors of overall survival (OS) and progression-free survival (PFS) for patients who undergo watchful waiting (WW), and those who receive non-R-containing regimens, R-alone, and R-chemotherapy combinations. Conclusions: In the setting of contemporary practice with routine R use, stratifying patients into good, intermediate, and poor FLIPI risk groups predicts distinct outcomes in terms of OS and PFS. FLIPI remains an important prognostic index in the R era and should be used in clinical practices to support discussions about prognosis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu